239 related articles for article (PubMed ID: 22403683)
21. Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa?
Foguim Tsombeng F; Gendrot M; Robert MG; Madamet M; Pradines B
Malar J; 2019 Aug; 18(1):285. PubMed ID: 31443646
[TBL] [Abstract][Full Text] [Related]
22. Endoperoxide-based compounds: cross-resistance with artemisinins and selection of a Plasmodium falciparum lineage with a K13 non-synonymous polymorphism.
Paloque L; Witkowski B; Lelièvre J; Ouji M; Ben Haddou T; Ariey F; Robert A; Augereau JM; Ménard D; Meunier B; Benoit-Vical F
J Antimicrob Chemother; 2018 Feb; 73(2):395-403. PubMed ID: 29177421
[TBL] [Abstract][Full Text] [Related]
23. Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998-2009.
Thanh NV; Toan TQ; Cowman AF; Casey GJ; Phuc BQ; Tien NT; Hung NM; Biggs BA
Malar J; 2010 Jun; 9():181. PubMed ID: 20573274
[TBL] [Abstract][Full Text] [Related]
24. Artemisinin-Based Drugs Target the Plasmodium falciparum Heme Detoxification Pathway.
Ribbiso KA; Heller LE; Taye A; Julian E; Willems AV; Roepe PD
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495226
[TBL] [Abstract][Full Text] [Related]
25. Quantification of Free Ferriprotoporphyrin IX Heme and Hemozoin for Artemisinin Sensitive versus Delayed Clearance Phenotype Plasmodium falciparum Malarial Parasites.
Heller LE; Roepe PD
Biochemistry; 2018 Dec; 57(51):6927-6934. PubMed ID: 30513202
[TBL] [Abstract][Full Text] [Related]
26. Plasmodium falciparum kelch 13: a potential molecular marker for tackling artemisinin-resistant malaria parasites.
Mita T; Tachibana S; Hashimoto M; Hirai M
Expert Rev Anti Infect Ther; 2016; 14(1):125-35. PubMed ID: 26535806
[TBL] [Abstract][Full Text] [Related]
27. Functional analysis of Plasmodium falciparum subpopulations associated with artemisinin resistance in Cambodia.
Dwivedi A; Reynes C; Kuehn A; Roche DB; Khim N; Hebrard M; Milanesi S; Rivals E; Frutos R; Menard D; Mamoun CB; Colinge J; Cornillot E
Malar J; 2017 Dec; 16(1):493. PubMed ID: 29258508
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance.
Cerqueira GC; Cheeseman IH; Schaffner SF; Nair S; McDew-White M; Phyo AP; Ashley EA; Melnikov A; Rogov P; Birren BW; Nosten F; Anderson TJC; Neafsey DE
Genome Biol; 2017 Apr; 18(1):78. PubMed ID: 28454557
[TBL] [Abstract][Full Text] [Related]
29. Heme-artemisinin adducts are crucial mediators of the ability of artemisinin to inhibit heme polymerization.
Kannan R; Sahal D; Chauhan VS
Chem Biol; 2002 Mar; 9(3):321-32. PubMed ID: 11927257
[TBL] [Abstract][Full Text] [Related]
30. Molecular assessment of kelch13 non-synonymous mutations in Plasmodium falciparum isolates from Central African Republic (2017-2019).
Nzoumbou-Boko R; Panté-Wockama CG; Ngoagoni C; Petiot N; Legrand E; Vickos U; Gody JC; Manirakiza A; Ndoua C; Lombart JP; Ménard D
Malar J; 2020 May; 19(1):191. PubMed ID: 32448203
[TBL] [Abstract][Full Text] [Related]
31. Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum.
Duffey M; Sanchez CP; Lanzer M
Malar J; 2018 Mar; 17(1):121. PubMed ID: 29558913
[TBL] [Abstract][Full Text] [Related]
32. Artemisinin Action and Resistance in Plasmodium falciparum.
Tilley L; Straimer J; Gnädig NF; Ralph SA; Fidock DA
Trends Parasitol; 2016 Sep; 32(9):682-696. PubMed ID: 27289273
[TBL] [Abstract][Full Text] [Related]
33. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum.
Qidwai T; Yadav DK; Khan F; Dhawan S; Bhakuni RS
Curr Pharm Des; 2012; 18(37):6133-54. PubMed ID: 22670592
[TBL] [Abstract][Full Text] [Related]
34. Emergence and Spread of
Kobasa T; Talundzic E; Sug-Aram R; Boondat P; Goldman IF; Lucchi NW; Dharmarak P; Sintasath D; Fukuda M; Whistler T; MacArthur J; Udhayakumar V; Prempree P; Chinanonwait N
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378723
[TBL] [Abstract][Full Text] [Related]
35. Fighting drug-resistant Plasmodium falciparum: the challenge of artemisinin resistance.
Wongsrichanalai C; Sibley CH
Clin Microbiol Infect; 2013 Oct; 19(10):908-16. PubMed ID: 24033691
[TBL] [Abstract][Full Text] [Related]
36. Quinolines and artemisinin: chemistry, biology and history.
Bray PG; Ward SA; O'Neill PM
Curr Top Microbiol Immunol; 2005; 295():3-38. PubMed ID: 16265885
[TBL] [Abstract][Full Text] [Related]
37. Evolution of Plasmodium falciparum drug resistance: implications for the development and containment of artemisinin resistance.
Mita T; Tanabe K
Jpn J Infect Dis; 2012; 65(6):465-75. PubMed ID: 23183197
[TBL] [Abstract][Full Text] [Related]
38. Artemisinin resistance in Plasmodium falciparum: what is it really?
Ferreira PE; Culleton R; Gil JP; Meshnick SR
Trends Parasitol; 2013 Jul; 29(7):318-20. PubMed ID: 23768531
[TBL] [Abstract][Full Text] [Related]
39. Antimalarial efficacy of arteether against multiple drug resistant strain of Plasmodium yoelii nigeriensis.
Dutta GP; Bajpai R; Vishwakarma RA
Pharmacol Res; 1989; 21(4):415-9. PubMed ID: 2771860
[TBL] [Abstract][Full Text] [Related]
40. The interaction of artemisinin with malarial hemozoin.
Hong YL; Yang YZ; Meshnick SR
Mol Biochem Parasitol; 1994 Jan; 63(1):121-8. PubMed ID: 8183310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
